Latest Regulatory Approvals News

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Nex Metals and its Aboriginal partner WTAC have applied for a 100ha lease to build processing infrastructure for the Kookynie Tailings Project, while metallurgical tests show promising gold recovery rates and potential tungsten by-product.

Tivan has secured all necessary regulatory and heritage clearances to launch a maiden drilling campaign at Walshy’s Wall, a promising manganese-barite gossan with high-grade fluorite and polymetallic potential in the Northern Territory.

Piche Resources completed a $2.53 million entitlement offer, raising $728,324 from shareholders, with the underwriter stepping in to cover a $1.85 million shortfall. New shares and options are set to trade from 31 August 2026.

Aureka Limited has reported new high-grade gold intercepts extending mineralisation southwards at its St Arnaud Comstock project, reinforcing plans for near-term production using nearby milling capacity.

Australian Mines is poised to kick off a key drilling campaign at its Flemington Scandium Project, aiming to expand its already impressive resource and support plans to triple scandium production amid tightening supply.

Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.

Scentre Group reported a 24.6% jump in half-year profit to $974.5 million despite an 8.3% dip in revenue, driven by strategic sales and robust leasing activity. The group upgraded its full-year FFO and distribution guidance, highlighting a confident outlook.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.